Amicus Therapeutics, Inc. Earnings

Amicus Therapeutics, Inc.’s revenue jumped 22.12% since last year same period to $154.69Mn in the Q2 2025. On a quarterly growth basis, Amicus Therapeutics, Inc. has generated 23.5% jump in its revenue since last 3-months.

Amicus Therapeutics, Inc.’s net profit fell -55.57% since last year same period to $-24.42Mn in the Q2 2025. On a quarterly growth basis, Amicus Therapeutics, Inc. has generated -12.61% fall in its net profits since last 3-months.

Amicus Therapeutics, Inc.’s net profit margin fell -27.39% since last year same period to -15.79% in the Q2 2025. On a quarterly growth basis, Amicus Therapeutics, Inc. has generated 8.82% jump in its net profit margins since last 3-months.

Amicus Therapeutics, Inc.’s earning per share (EPS) estimates for the current quarter stand at 0.02 - a 121.27% jump from last quarter’s estimates.

Amicus Therapeutics, Inc.’s earning per share (EPS) estimates for the current year stand at 0.02.

Amicus Therapeutics, Inc.’s earning per share (EPS) jumped 100% since last year same period to 0 in the Q3 2025. This indicates that the Amicus Therapeutics, Inc. has generated 100% annual rate of jump in its earning per share (EPS) in the last 4 quarters.